# UCSF Helen Diller Family Comprehensive Cancer Center

Source: https://onco.cc/institutions/ucsf/  
OnCo record `ucsf` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

UCSF is the birthplace of oncogene biology (Bishop, Varmus) and KRAS G12C drugging (Shokat), and a leader in I-SPY adaptive breast trials.

## Summary

The UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco is the birthplace of oncogene biology, where Bishop and Varmus made their Nobel-winning discovery, and of KRAS G12C drugging through Shokat's switch-II pocket; it holds NCI comprehensive designation and ranks thirty-third in the Newsweek/Statista oncology list. It leads the I-SPY 2 adaptive platform trial in breast cancer under Laura J. Esserman, runs the UCSF500 panel, and pioneered PSMA PET with Thomas A. Hope, alongside neuro-oncology and prostate programmes. OnCo links it to KRAS and PSMA, to gallium-68 PSMA-11, to the Ostrem and Shokat paper, and to the MYC and telomere pathways. Whether MYC can be drugged directly, and tolerated, is the open question it is linked to. Alan Ashworth, Eric J. Small and Alan P. Venook are among the people listed.

## Fields

- Kind: Institution
- Last checked: 2026-09-04
- City: San Francisco, US
- Type: cancer-center
- NCI designation: comprehensive
- Website: https://cancer.ucsf.edu

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/UCSF_Helen_Diller_Family_Comprehensive_Cancer_Center
- Official website: https://cancer.ucsf.edu

## Connected records

- technologies: [Gamma Knife](https://onco.cc/technologies/gamma-knife/), [PSMA PET](https://onco.cc/technologies/psma-pet/), [Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS)](https://onco.cc/technologies/radiosurgery-srs/)
- targets: [KRAS](https://onco.cc/targets/kras/), [PSMA](https://onco.cc/targets/psma/)
- terms: [Basket, umbrella, and platform trials](https://onco.cc/terms/basket-umbrella-platform/)
- people: [Ajai Chari](https://onco.cc/people/ajai-chari/), [Alan Ashworth](https://onco.cc/people/alan-ashworth/), [Alan P. Venook](https://onco.cc/people/alan-venook/), [Emily K. Bergsland](https://onco.cc/people/emily-bergsland/), [Eric J. Small](https://onco.cc/people/eric-small/), [Frank McCormick](https://onco.cc/people/frank-mccormick/), [Helen Diller](https://onco.cc/people/helen-diller/), [Jeffrey A. Bluestone](https://onco.cc/people/jeffrey-bluestone/), [Katherine K. Matthay](https://onco.cc/people/katherine-matthay/), [Kevan M. Shokat](https://onco.cc/people/kevan-shokat/), [Laura J. Esserman](https://onco.cc/people/laura-esserman/), [Mitchel S. Berger](https://onco.cc/people/mitchel-berger/), [Priscilla Chan](https://onco.cc/people/priscilla-chan/), [Rahul Aggarwal](https://onco.cc/people/rahul-aggarwal/), [Robin Kate Kelley](https://onco.cc/people/robin-kate-kelley/), [Sanford I. Weill](https://onco.cc/people/sanford-weill/), [Sean Parker](https://onco.cc/people/sean-parker/), [Thomas A. Hope](https://onco.cc/people/thomas-hope/)
- drugs: [Gallium-68 gozetotide (PSMA-11)](https://onco.cc/drugs/ga68-psma-11/)
- key papers: [Binnewies 2018: understanding the tumour immune microenvironment for effective therapy](https://onco.cc/key-papers/paper-binnewies-tumor-immune-microenvironment-natmed-2018/), [Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival](https://onco.cc/key-papers/paper-magbanua-ispy2-ctdna-neoadjuvant-ann-oncol-2021/), [Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial](https://onco.cc/key-papers/paper-psma-prerp-hope-jama-oncol-2021/), [Genetic mechanisms of immune evasion in colorectal cancer](https://onco.cc/key-papers/paper-grasso-immune-evasion-colorectal-cancer-discov-2018/), [MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition](https://onco.cc/key-papers/paper-horiuchi-myc-tnbc-cdk-synthetic-lethal-jem-2012/), [Ostrem and Shokat: the hidden pocket that made KRAS G12C druggable](https://onco.cc/key-papers/paper-ostrem-kras-g12c-nature-2013/), [Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy](https://onco.cc/key-papers/paper-collisson-pancreatic-subtypes-nat-med-2011/)
- institutions: [Chan Zuckerberg Biohub](https://onco.cc/institutions/cz-biohub/), [Damon Runyon Cancer Research Foundation](https://onco.cc/institutions/damon-runyon/), [Emerson Collective](https://onco.cc/institutions/emerson-collective/), [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/), [Parker Institute for Cancer Immunotherapy](https://onco.cc/institutions/parker-institute/)
- pathways: [Inflammation & NF-κB](https://onco.cc/pathways/inflammation-nfkb/), [mRNA translation (eIF4F / mTOR)](https://onco.cc/pathways/mrna-translation-eif4f/), [MYC](https://onco.cc/pathways/myc/), [Telomere maintenance & replicative immortality](https://onco.cc/pathways/telomere-maintenance/)
- ideas: [Can MYC be drugged directly, and will patients tolerate it?](https://onco.cc/ideas/idea-drugging-myc/)
- trials: [I-SPY 1 (CALGB 150007/150012, ACRIN 6657)](https://onco.cc/trials/i-spy-1/), [I-SPY 2](https://onco.cc/trials/i-spy-2/), [I-SPY 2.2](https://onco.cc/trials/i-spy-2-2/), [PSMA-PreRP](https://onco.cc/trials/psma-prerp/), [WISDOM (Women Informed to Screen Depending on Measures of Risk)](https://onco.cc/trials/wisdom-trial/)
- companies: [Quantum Leap Healthcare Collaborative](https://onco.cc/companies/quantum-leap-healthcare-collaborative/)

---
JSON: https://onco.cc/api/v1/entities/ucsf.json